KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
145 hedge funds and large institutions have $714M invested in KalVista Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 24 closing their positions.
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
33% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $10.6M
26% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 38
16% more capital invested
Capital invested by funds: $616M → $714M (+$98.5M)
6.51% more ownership
Funds ownership: 109.51% → 116.03% (+6.5%)
4% more funds holding
Funds holding: 139 → 145 (+6)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$24.3M |
| 2 |
Goldman Sachs
New York
|
+$23M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$14.6M |
| 4 |
FGP
Freestone Grove Partners
San Francisco,
California
|
+$9.73M |
| 5 |
SCM
Sio Capital Management
New York
|
+$9.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$54.2M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.6M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$6.48M |
| 4 |
SC
Stempoint Capital
New York
|
-$4.56M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.65M |
KALV Hedge Fund Activity: Q3 2025 in Review
145 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2025, worth a combined $714M — up 16% from $616M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KALV positions and 24 closed out — a net gain of 8 holders — while 48 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $24.3M. The largest seller was Vestal Point Capital, cutting an estimated $54.2M.
- 145 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2025, up from 139 in Q2 2025.
- Funds reported $714M of KalVista Pharmaceuticals stock for Q3 2025, up 16% quarter-over-quarter.
- 32 funds opened new KalVista Pharmaceuticals positions in Q3 2025 and 24 closed out, a net change of +8 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2025 was Millennium Management, an estimated $24.3M added.
- The largest KalVista Pharmaceuticals seller in Q3 2025 was Vestal Point Capital, an estimated $54.2M sold.
Based on aggregated 13F filings for Q3 2025.